Gastroenterology & Hepatology

Gastroenterology & Hepatology

EmailEmail    |   Bookmark Page Bookmark  |   RSS Feeds RSS  |   Print Page Print  

 
Lilani Perera, MD
Assistant Professor
Doctor of Medicine (MD)
2000:University of Colombo, SriLanka
Residency
2001-2004:Saint Barnabas Medical Center, Livingston, NJ
Post Doctoral Fellowship, Immunobiology
2004-2005:Mount Sinai School of Medicine, NY
Fellowship
2005-2008: Gastroenterology, Medical College of Wisconsin Affiliated Hospitals
 
 Clinical Interests & Patient Appointments 

 

  

PUBLICATIONS (To view complete Curruculum Vitae, click here)

 

Manuscripts

  1. Perera L, Mayer L. Immunologic defects underlying the IBD. Gastroenterology &   Hepatology. 2005 September;1(2):108-116.
     
  2. Zauber NP, Sabbath SA, Morata S, Perera LP. Adequacy of colonoscopic biopsy specimens for molecular analysis: a comparative study with colectomy tissue. Diagnostic Molecular Pathology. 2006 September;15(3):162-8.
     
  3. Perera LP, Jabri Bana, Saho Ling, Patel A, Mayer L: Class 1b expression defect in IBD epithelial cells: lack of coordinate regulation of CD1d and the epithelially expressed CD8 ligand, gp180. Inflammatory Bowel Diseases. 2007 March;13(3):298- 307.
     
  4. Perera L, Kern M, Hofmann C, Tatro L, Chai K, Kuribayashi S, Lawal A, Shaker R. Manometric evidence for a phonation-induced UES contratile reflex. American Journal of Physiology, Gastrointestinal and Liver Physiology. 2008 April;294(4):G885-891.
     
  5. Ananthakrishnan AN, Beaulieu DB, Ulitsky A, Zadvornova Y, Skaros S, Johnson K, Naik A, Perera L, Issa M, Binion DG, Saeian K. Does primary sclerosing cholangitis impact quality of life in patients with inflammatory bowel disease? Inflammatory Bowel Diseases. 2010 March;16(3):494-500.
     
  6. Kuribayashi S, Massey BT , Hafeezullah M,  Perera LP, Hussaini S, Tatro L,  Darling R, Franco R,  Shaker R.  Upper esophageal sphincter and gastroesophageal junction pressure changes act to prevent gastroesophageal and esophagopharyngeal reflux during apneic episodes in patients with obstructive sleep apnea. Chest. 2010 April;137(4):769-776.

 

Abstracts

 

  1. Beuria P, Panja A, Kraus T, Perera L, Sperber K: Human intestinal epithelial cells constitutively express the B7h co stimulatory molecule. Gastroenterology. 2001 April;120(5, suppl 1): A-318(1643).
     
  2. Yio X, Korsten C, Friedman C, Park M, Yio J, Roth-Walter F, Perera L, Kamalu O, Mayer L. Carcinoembryonic antigen expressing cells preferentially activate CD8+ T cells.  Gastroenterology. 2006 April;130(4, suppl 2): A-693(W 1616).
     
  3. Perera L, Chai K, Hoffman C, Rittman T, Kern M, Shaker R. Effect of phonation on the luminal pressures of the esophagus and its sphincters. Gastroenterology. 2006 April; 130(4, suppl 2):  A-729(W1790).
     
  4. Bajaj S, Blom D, Antonik SJ, Mepani R, Kern MK, Chai K, Perera LP, Hofmann C, Shaker R. Comparison of the effect of Dor procedure and Nissen fundoplicationon the dispensability of gastroesophageal junction; an intraoperative study. Gastroenterology. 2007 April;132(4, suppl 2): A-51(M1437).
     
  5. Perera LP, Kern MK, Tatro L, Hofmann C, Kuribayashi S, Chai K, Shaker R. New insight into phonation induced increase in the upper esophageal sphincter pressure; contraction vs compression. Gastroenterology. 2007 April; 132(4, suppl 2): A595(T1973).
     
  6. Perera LP, Tatro L, Hoffman C, Kern MK, Shaker R. Gender affects phonation related UES contraction. 2007 April;132(4, suppl 2): A-93(T1963).
     
  7. Perera LP, Hofmann C, Hogan WJ, Massey BT. Use of amyl nitrite test to assess impaired LES relaxation during manometry. Gastroenterology. 2007 April;132(4, suppl 2): A26(136).
     
  8. Perera LP, Hofmann C, Hogan WJ, Massey BT. Use of the amyl nitrite test to assess impaired LES relaxation during manometry. Gastroenterology 2007;132(suppl 2): A26-27.
     
  9. Perera LP, Hoffmann C, Tatro L, Hogan W, Massey B.  Exaggerated LES rebound contractions following amyl nitrite in achalasia patients:  is this inhibitory denervation hypersensitivity?
     
  10. Qumseya B, Naik AS, Ashwin N Ananthakrishnan, Zadvornova Y, Skaros S, Johnson K, Perera LP, Binion DG, Issa M. Increased BMI is not associated with dose escalation or failure of adalimumab therapy in Crohn’s disease. Gastroenterology 2009;136(Suppl 1): W1106.
     
  11. Naik AS, Qumseya B, Ashwin N Ananthakrishnan, Zadvornova Y, Skaros S, Beaulieu BD, Johnson K, Perera LP, Binion DG, Issa M. Anti-TNF therapy for Crohn’s disease: predictors of dose escalation and early discontinuation by 1 year of therapy. Gastroenterology 2009;136 (Suppl 1): W1102.
     
  12. Beaulieu DB, Ashwin N Ananthakrishnan, Zadvornova Y, Stein DJ, Mepani R, Antonik SJ, Skaros S, Johnson K, Naik AS, Perera LP, Binion DG. Seasonal variation in HRQoL and disease activity in patients with inflammatory bowel disease: a tertiary care center experience. Gastroenterology 2009;136(Suppl 1): M1158.
     
  13. Beaulieu DB, Ashwin N Ananthakrishnan, Zadvornova Y, Stein DJ, Mepani R, Antonik SJ, Skaros S, Johnson K, Naik AS, Perera LP, Binion DG. Does duration of disease impact Health Related Quality of Life (HRQoL) in Inflammatory Bowel Disease? Gastroenterology 2009;136 (Suppl 1): M1156.
     
  14. Venu M, Naik AS, Ashwin N Ananthakrishnan, Zadvornova Y, Skaros S, Johnson K, Perera LP, Binion DG, Issa M. Early Infliximab infusion in hospitalized severe UC patients: one year outcome. Gastroenterology 2009;136(Suppl 1): S1152.
     
  15. Chiplunker A, Ashwin N Ananthakrishnan, Beaulieu DB, Naik AS,  Zadvornova Y, Skaros S, Johnson K, Perera LP, Binion DG, Issa M. Long-term impact of Clostridium difficile on inflammatory bowel disease. Gastroenterology 2009;136(Suppl 1): S1145.
     
  16. Ashwin N Ananthakrishnan, Beaulieu DB, Naik AS, Zadvornova Y, Skaros S, Johnson K, Perera LP, Issa M, Binion DG, Saeian K. Does primary sclerosing cholangitis impact quality of life in patients with inflammatory bowel disease? Gastroenterology 2009;136(Suppl 1): S1160.
     
  17. Kumar N, Ananthakrishnan AN, Zadvornova  Y, Issa M, Naik AS, Perera LP.  Durablility of Infliximab in Ulcerative Colitis: a tertiary center experience. Presented as a poster at Digestive Disease Week 2010.
     
  18. Perera LP, Ananthakrishnan AN, Zadvornova Y, Issa M, Naik AS, Skaros S, Johnson K, Tyler K,  Ward A,  Massey B.  High prevalence of obstructive defecation in Inflammatory Bowel Disease patients in remission.  Presented as a poster at Digestive Disease Week 2010.
     
  19. Ananthakrishnan AN,  Naik AS,  Zadvornova Y,  Issa M, Skaros S,  Johnson K,  Tyler K,  Ward A,  Perera, LP.  Pregnancy and Health Related Quality of Life (HRQoL) in IBD: A tertiary care observational Study.  Presented as a poster at Digestive Disease Week 2010.
     
  20. Venu M, Naik AS,  Ananthakrishnan AN,  Zadvornova Y, Skaros S, Johnson K,  Perera LP,  Binion D,  Issa M.  Early Infliximab infusion in hospitalized severe UC patients: two year outcome. Presented as a poster at Digestive Disease Week 2010.
     
  21. Zadvornova Y,  Ananthakrishnan AN, Stein D,  Skaros S,  Johnson K,  Naik AS,  Perera LP,  Issa M.  Infliximab monotherapy vs. combined Infliximab-immunomodulator therapy in Ulcerative Colitis.  Presented as a poster at Digestive Disease Week 2010.
     
  22. Naik AS, Zadvornova Y,  Issa M,  Skaros S, Ward A,  Johnson K, Tyler K,  Stein D,  Perera LP,  Ananthakrishnan, AN.  Tubular Adenoma and Low Grade Dysplasia in Inflammatory Bowel Disease: Who is at risk?  Presented as a poster at Digestive Disease Week 2010.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

webmaster@mcw.edu
© 2012 Medical College of Wisconsin
Page Updated 03/13/2012